VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
Illustration for: Unitree's STAR Market IPO Subscription Opens at $9B
Value Add VC/Pulse/IPOFOLLOW-UP

Unitree's STAR Market IPO Subscription Opens at $9B

Unitree's Shanghai STAR Market IPO subscription formally opened at a roughly $9 billion valuation, the first profitable, scaled humanoid robotics company to go public on a major exchange.

TC
Trace Cohen
Early-stage VC & angel · Founder, New York Venture Partners
August 10, 2026
1 min read
ShareXLinkedInEmail

THE RUNDOWN

1

Unitree's STAR Market IPO subscription opened today, pricing shares at 150.80 yuan for a total market capitalization of roughly ¥61 billion ($9.0B), with payment due within two days

2

The company plans to issue 40.45 million shares -- 10% of post-offering capital -- and expects to raise about 6.1 billion yuan ($901M)

3

Unitree becomes the first profitable, revenue-generating humanoid robotics company to list on a major public market, a contrast to loss-making Western humanoid peers still burning cash pre-revenue

4

DeepSeek is among Unitree's strategic IPO investors, tying two of China's most closely watched AI and robotics names to the same listing

TC

The VC Read · Trace's Take

Trace Cohen

The real story isn't the $9B price -- it's that Unitree is profitable going into this listing, which no Western humanoid robotics company can claim; Figure and 1X are still burning cash on private-round valuations that assume years more runway before revenue. Use Unitree's public pricing as the actual comp the next time a humanoid robotics term sheet cites a 'category-leading' valuation -- $9B for profitable and shipping is now the number to beat, not a private mark. DeepSeek's strategic stake is worth tracking separately: it's a bet on humanoid robotics compute demand feeding back into DeepSeek's own model roadmap.

AI Valuations Tracker →

Analysis

Unitree's STAR Market IPO subscription formally opened today on Shanghai's exchange, pricing shares at 150.80 yuan each for a total market capitalization of approximately ¥61 billion (about $9.0 billion), according to BigGo Finance. Pulse previewed this exact subscription date more than a week ago; today's opening confirms the timeline and locks in pricing that had only been indicated during preliminary inquiry.

What's changed since Pulse's preview: pricing is now final, not indicative. Unitree will issue 40.45 million shares -- 10% of post-offering capital, bringing total shares outstanding to roughly 404 million -- and expects to raise about 6.1 billion yuan (roughly $901 million). Offline and online subscriptions are running simultaneously, with payment due within two days of open.

“What's changed since Pulse's preview: pricing is now final, not indicative.”

The listing is notable for what Unitree is, not just its price: a profitable, revenue-generating humanoid robotics company going public on a major exchange, a contrast to Western humanoid peers like Figure and 1X that remain pre-revenue or early-revenue and privately funded at comparable or higher valuations. Pulse has covered how Unitree's IPO gives humanoid robotics a real price tag against Figure and Tesla's Optimus program -- a $9 billion public valuation for a profitable company is now the actual market comparable those private rounds get measured against, not just a projection.

DeepSeek is among Unitree's strategic IPO investors, a detail that ties two of the most closely watched Chinese AI names to the same listing and adds a second axis of investor attention beyond the robotics story alone. The subscription follows Unitree formalizing its IPO plans just days after new US export sanctions, underscoring that Chinese hardware AI companies are moving toward public capital markets on their own timeline regardless of US trade posture.

ShareXLinkedInEmail

Reported by BigGo Finance · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.

Read Next

IPO· Aug 9, 2026

Caris Leads a Wild Week for Recent IPO Stocks

Illustration for: Caris Leads a Wild Week for Recent IPO Stocks
IPO

Caris Leads a Wild Week for Recent IPO Stocks

Caris Life Sciences jumped 21.6% on a beat-and-raise quarter while BillionToOne fell 29.8% despite beating estimates, the sharpest split in the Renaissance IPO Index in weeks.

IPO· Aug 9, 2026

BillionToOne's Selloff Is a Warning for Biotech IPOs

Illustration for: BillionToOne's Selloff Is a Warning for Biotech IPOs
IPO

BillionToOne's Selloff Is a Warning for Biotech IPOs

BillionToOne beat Q2 estimates by a wide margin and still fell nearly 30% because it reiterated rather than raised guidance -- a signal about how little room newly public companies have left to disappoint.

IPO· Aug 9, 2026

Attovia Therapeutics Climbs 29% After $289M IPO

Illustration for: Attovia Therapeutics Climbs 29% After $289M IPO
IPO$289M IPO

Attovia Therapeutics Climbs 29% After $289M IPO

Attovia Therapeutics priced an upsized $289 million IPO and climbed 29% on debut, the fourth biotech in two weeks to price well above its original terms.

@Trace_Cohen·t@nyvp.com